Summary
The results from the 2-year AIM (ABA in Inadequate responders to MTX) trial indicated that RA patients refractory to treatment with MTX, demonstrate significant reduction in radiographic progression after treatment with Abatacept [Ann Rheum Dis 2005;64(Suppl III):56].
- rheumatology clinical trials
- rheumatoid arthritis
- © 2006 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.